{"url_path":"/sec/clpt/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 OTHER INFORMATION.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1285550/0001193125-26-221890-index.html","accession_number":"0001193125-26-221890","cik":"0001285550","ticker":"CLPT","issuer_name":"ClearPoint Neuro, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1285550/0001193125-26-221890-index.html","primary_entity_key":"0001285550","primary_entity_name":"ClearPoint Neuro, Inc."},"word_count":47,"has_tables":true,"body_markdown":"ITEM 5. OTHER INFORMATION.\n\n(a) None.\n\n(b) None.\n\n(c) During the quarter ended March 31, 2026, none of our officers or directors adopted or terminated a \"Rule 10b5-1 trading arrangement\" or \"non-Rule 10b5-1 trading arrangement,\" as each term is defined in Item 408 of Regulation S-K.\n\n \n\n30"}